Multiple Myeloma (Plasma Cell Neoplasm): Modern Treatment and Outcomes — Cost, Top Hospitals & Success Rates | MyMedicPlus

Multiple myeloma (MM) is a malignant neoplasm of plasma cells — antibody-producing B lymphocytes that reside in the bone marrow. It is classified as a plasma cell neoplasm within the broader category of B-cell lymphoproliferative disorders. Plasma cells in multiple myeloma proliferate uncontrollably within the bone marrow, producing abnormal quantities of a single monoclonal immunoglobulin protein (the M-protein or paraprotein), crowding out normal haematopoiesis, destroying bone, impairing renal function, and suppressing normal immune function. Multiple myeloma accounts for approximately 10% of all haematological malignancies and 1% of all cancers, with an annual incidence of approximately 7 per 100,000 in Western countries.

The clinical presentation of multiple myeloma is summarised by the CRAB criteria: hyperCalcaemia (elevated serum calcium), Renal insufficiency (creatinine >177 μmol/L or eGFR <40 mL/min), Anaemia (haemoglobin <100 g/L), and Bone lesions (lytic bone lesions, pathological fractures, or osteoporosis). Additional defining criteria include clonal bone marrow plasma cell percentage ≥60%, involved/uninvolved serum free light chain ratio ≥100, and more than one focal lesion on MRI. The disease spectrum ranges from the pre-malignant precursors (monoclonal gammopathy of undetermined significance — MGUS, and smouldering multiple myeloma — SMM) to active multiple myeloma requiring treatment.

Treatment of multiple myeloma has been transformed over the past two decades by the introduction of novel therapeutic agents — proteasome inhibitors (bortezomib, carfilzomib, ixazomib), immunomodulatory drugs (thalidomide, lenalidomide, pomalidomide), and most recently anti-CD38 monoclonal antibodies (daratumumab, isatuximab) — which have dramatically improved response rates, depth of response, and overall survival. Autologous stem cell transplantation (ASCT) remains a central component of first-line treatment in eligible patients, consolidating the response achieved with induction therapy. Despite these advances, multiple myeloma remains incurable in the vast majority of patients, with the disease following a relapsing-remitting course requiring sequential lines of therapy.

Multiple myeloma treatment addresses the primary malignant disease and its extensive systemic complications. Active multiple myeloma requiring treatment is defined by the presence of CRAB criteria or myeloma-defining events. Symptomatic bone disease — the most common presentation, affecting >80% of patients — manifests as bone pain (particularly axial skeleton: vertebral compression fractures, rib fractures), pathological fractures, and hypercalcaemia requiring bisphosphonate therapy (zoledronic acid or denosumab) alongside systemic treatment. Myeloma nephropathy — a major cause of morbidity and mortality — requires concurrent nephrology management with attention to hydration, avoidance of nephrotoxins, treatment of hypercalcaemia and light chain cast nephropathy, and potentially dialysis support.

Anaemia from bone marrow infiltration causes significant fatigue and reduced quality of life, requiring erythropoiesis-stimulating agents or transfusion support in addition to myeloma treatment. Hyperviscosity syndrome from high paraprotein levels may require urgent plasmapheresis. Spinal cord compression from vertebral collapse or plasmacytoma requires emergency radiotherapy and/or neurosurgical decompression. Peripheral neuropathy — a major treatment-related complication of thalidomide and bortezomib — requires dose modification and symptomatic management. Infections from immune suppression (particularly pneumococcal pneumonia, herpes zoster, and Pneumocystis jirovecii pneumonia) require prophylactic antimicrobials and vaccination.

Treatment eligibility in multiple myeloma is primarily determined by transplant eligibility (fit vs frail) and disease characteristics. Transplant-eligible patients (typically age <70-75 with good performance status and adequate organ function) receive induction therapy — typically a triplet or quadruplet regimen such as VRd (bortezomib, lenalidomide, dexamethasone) or Dara-VRd (daratumumab added) for 4-6 cycles — followed by autologous stem cell transplantation and lenalidomide maintenance. Transplant-ineligible patients (elderly, frail, or significant comorbidities) receive continuous treatment with less intensive regimens such as VRd, VMP (bortezomib, melphalan, prednisone), or Rd (lenalidomide, dexamethasone), often with daratumumab added.

Contraindications to specific treatment components must be assessed individually. Bortezomib requires monitoring for and dose modification with peripheral neuropathy. Lenalidomide requires dose adjustment for renal impairment. Thalidomide is absolutely contraindicated in pregnancy (severe teratogenicity) and requires REMS programme enrolment in many countries. Autologous stem cell transplantation requires adequate cardiac and pulmonary reserve, absence of active infection, and adequate stem cell collection. Daratumumab can cause infusion reactions and may interfere with blood bank cross-matching requiring prior notification.

First-line treatment for transplant-eligible patients is typically four cycles of induction with VRd (bortezomib 1.3 mg/m², lenalidomide 25 mg days 1-14 per 21-day cycle, dexamethasone 40 mg weekly) or Dara-VRd (adding daratumumab 16 mg/kg), followed by peripheral blood stem cell collection and high-dose melphalan (200 mg/m²) conditioning with ASCT. Post-transplant maintenance with lenalidomide 10-15 mg daily improves progression-free survival by 50% and overall survival in multiple trials. For transplant-ineligible patients, the MAIA trial established daratumumab-lenalidomide-dexamethasone (DRd) as a new standard of care with superior outcomes versus Rd alone.

Relapsed and refractory multiple myeloma (RRMM) requires sequential lines of therapy. Second-line options depend on prior treatment, renal function, and performance status — options include carfilzomib-based regimens, pomalidomide-based regimens, venetoclax in t(11;14) translocation patients, and more recently bispecific T-cell engagers (teclistamab, elranatamab targeting BCMA) and chimeric antigen receptor T-cell (CAR-T) therapy (idecabtagene vicleucel, ciltacabtagene autoleucel), which have achieved remarkable response rates even in heavily pre-treated patients. Allogeneic stem cell transplantation is a curative option in a small minority of younger fit patients but carries high treatment-related mortality (20-30%). CAR-T cell therapies (idecabtagene vicleucel, ciltacabtagene autoleucel) targeting BCMA have demonstrated deep and durable responses in heavily pre-treated relapsed/refractory myeloma, with overall response rates of 70–90% and complete response rates of 40–70%, establishing this modality as an important salvage option after failure of multiple prior regimens.

The prognosis for multiple myeloma has improved substantially over the past 20 years. The introduction of novel agents has extended median overall survival from approximately 2-3 years in the late 1990s to 6-8 years in the current era for newly diagnosed patients. For patients achieving complete remission (CR) or minimal residual disease (MRD) negativity — now achievable in 30-60% of newly diagnosed patients with modern quadruplet induction and ASCT — 10-year overall survival is projected to exceed 40-50% in some series. MRD negativity by next-generation flow cytometry or sequencing is associated with significantly prolonged progression-free survival and may allow treatment-free intervals.

The MAIA trial (daratumumab-Rd) reported a 5-year PFS rate of 52% and OS rate of 66% in transplant-ineligible newly diagnosed patients — remarkable outcomes that would have been inconceivable a decade ago. CAR-T cell therapies in RRMM demonstrate overall response rates of 73-98% and complete remission rates of 33-67% even in patients who have failed 3 or more prior lines of therapy, offering genuine hope for patients who previously had few options. Supportive care advances — including bone-protective bisphosphonates, prophylactic antiviral therapy, erythropoiesis-stimulating agents, and improved antimicrobial prophylaxis — have substantially reduced morbidity from disease complications.

Multiple myeloma treatment carries significant treatment-related toxicity. Bortezomib causes peripheral neuropathy in 30-40% of patients (often dose-limiting), thrombocytopenia, and fatigue. Lenalidomide causes myelosuppression (anaemia, neutropenia), venous thromboembolism (requiring prophylactic anticoagulation), and is potentially carcinogenic (second primary malignancies in long-term maintenance). Dexamethasone causes hyperglycaemia, fluid retention, insomnia, infections, and adrenal suppression with long-term use. Daratumumab causes infusion reactions (grade 3/4 in 5-10% of patients), increased susceptibility to infections, and can interfere with blood bank typing assays.

High-dose melphalan conditioning for ASCT causes severe mucositis, pancytopenia requiring blood product support and growth factor administration, and infectious complications (bacterial, fungal, and viral) requiring prophylactic medications. Treatment-related mortality from ASCT at experienced centres is approximately 1-3%. CAR-T cell therapy is associated with cytokine release syndrome (CRS — fever, hypotension, hypoxia) and immune effector cell-associated neurotoxicity syndrome (ICANS) in a significant proportion of patients, requiring specialised inpatient management at certified apheresis centres. Long-term myeloma survivors face risks of second primary malignancies and long-term organ toxicity from cumulative treatment exposure.

Patients on maintenance lenalidomide following ASCT are monitored monthly for blood counts (CBC, differential), quarterly for M-protein quantification (serum protein electrophoresis, immunofixation, serum free light chains), and annually for bone marrow assessment if considering treatment-free intervals. Whole-body PET-CT or MRI is performed at 1-2 year intervals to monitor skeletal disease and detect new bone lesions. Bone protection with intravenous zoledronic acid every 3-4 months (or subcutaneous denosumab) is continued for at least 2 years in patients with active bone disease.

Long-term survivorship monitoring addresses treatment-related late effects: annual echocardiogram for carfilzomib-treated patients (risk of cardiomyopathy), regular neurological assessment and neuropathy management for bortezomib/thalidomide patients, osteoporosis monitoring and bone density DEXA scanning, screening for second primary malignancies (particularly in lenalidomide maintenance patients), and cardiovascular risk factor management. Quality of life assessment and fatigue management are integrated into routine follow-up visits. Patients are connected with myeloma patient support organisations (Myeloma UK, International Myeloma Foundation) for peer support, information, and clinical trial access.

Multiple myeloma treatment is among the most expensive in oncology. In the USA, first-line VRd induction therapy costs USD 120,000-200,000 for 4 cycles; ASCT costs USD 150,000-250,000 including hospitalisation; lenalidomide maintenance at USD 20,000-25,000 per month for an indefinite period makes the annual cost of maintenance alone USD 240,000-300,000. CAR-T cell therapies are priced at USD 450,000-600,000 per infusion. These costs are partially offset by insurance coverage in the USA and by NHS formulary in the UK, though access restrictions, prior authorisation requirements, and copayments create significant financial toxicity.

Medical tourism for multiple myeloma treatment is relevant for patients in countries where novel agents are not reimbursed or where waiting times for ASCT are prohibitive. India offers haematological malignancy treatment at internationally accredited hospitals (Tata Memorial Hospital, AIIMS, Apollo, Manipal) with access to most novel agents at 40-70% of US private costs. Bortezomib, lenalidomide, and thalidomide are available as generics in India, substantially reducing treatment costs. For international patients seeking ASCT, Indian accredited hospitals perform over 2,000 ASCT procedures annually with outcomes comparable to Western centres, at total procedure costs of USD 25,000-50,000 versus USD 150,000-250,000 in the USA.

For smouldering multiple myeloma (SMM) — the asymptomatic precursor state — the standard approach is watchful waiting with 3-6 monthly monitoring (no treatment unless progression to active myeloma), based on evidence that early treatment does not improve OS and exposes patients to unnecessary toxicity. The GEM-CESAR trial showed that early treatment of high-risk SMM with quadruplet induction and ASCT achieves high rates of MRD negativity and may alter the disease course, but this approach remains investigational outside clinical trials.

Within the myeloma treatment armamentarium, oral vs intravenous vs subcutaneous administration routes provide practical alternatives — subcutaneous daratumumab and subcutaneous bortezomib offer equivalent efficacy to intravenous formulations with reduced infusion time and improved convenience. Clinical trial participation should be actively considered at all stages of myeloma treatment, as numerous novel agents (bispecific antibodies, antibody-drug conjugates, next-generation CAR-T constructs, cereblon E3 ligase modulators — CELMoDs such as iberdomide) are advancing through trial phases with promising results.